It looks like the perfect storm is coming Virax's way.(1)...

It looks like the perfect storm is coming Virax's way.

(1) Upcoming publication in peer review journal
(2) Release of a large African trial results
(3) Progress with Transgene

The market cap is still below $20m, which suggests to me that the market isn't putting too much "belief" in the platform technology and VIR-201. And looking at the balance sheet I don't blame them.

But Transgene, using the technology platform, have in fact managed to get some runs on the board in clinical trials and strike some deals with large pharma.

The early trial for VIR201 did provide some interesting results albeit in a small patient sample. This trial should address the size issue. The question now is whether it works or not... and results are coming in a week or two.

If positive, I would expect a major rerating is possible. I just hope that management get the good news story out to the news wires, if in fact the results prove positive.

Very exciting times for Virax, patients and shareholders. We've waited years for this trial... let's hope it's a good one.